PI3K
3 abstracts
Abstract
Genomics to select treatment for patients (pts) with metastatic cancer: Final analysis of Molecular Tumor Board (MTB) evaluations in the ROME trial.Org: IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy, Department of Clinical and Molecular Medicine, Oncology Unit, Sant’ Andrea University Hospital, Sapienza University of Rome, Roma, Italy, Dipartimento di Eccellenza in Medicina Molecolare e Biotecnologie Mediche, Università Federico II, Napoli UOC PATOLOGIA CLINICA - Ospedale San Giovanni Addolorata, Roma, Rome, Italy, Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy,
Abstract
Clinical outcomes of retreatment with daratumumab-based regimens in anti-CD38 refractory multiple myeloma.Org: Myeloma Service, Department of Medicine, Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center, New York, NY, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA,
Abstract
A combination of circulating tumor cell (CTC) and cancer stem cell (CSC) markers to predict the prognosis of breast cancer.Org: Baylor College of Medicine Division of Hematology and Oncology, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Texas MD Anderson Cancer Center, Baylor College of Medicine,